Latest Articles

Publication Date
Correction to: Efficacy and Safety of 48-Week Low-Dose Dienogest Treatment in Patients with Endometriosis-Associated Dysmenorrhea: A Randomized, Open-Label, Parallel-Group Trial.

Published: Dec. 24, 2025, midnight
Feasibility and clinical value of virtual reality based on 3D model in colorectal endometriosis for surgical planning.

Colorectal endometriosis (CRE) is one of the most severe forms of deep pelvic endometriosis with a high risk of major postoperative complications. While pelvic MRI is the gold standard for …

Published: Dec. 24, 2025, midnight
The Histamine-Associated Inflammatory Landscape of Endometriosis: Molecular Profiling of HDC, HRH1-HRH4, and Cytokines Across Lesion Subtypes.

Pain in endometriosis involves not only nociceptive but also neuropathic and neurogenic components, reflecting its complex nature. Histamine, a biogenic amine, has emerged as a critical mediator connecting inflammation and …

Published: Dec. 24, 2025, midnight
First patient dosed in phase 3 trial evaluating ENHERTU in endometrial cancer - Investing.com Nigeria

First patient dosed in phase 3 trial evaluating ENHERTU in endometrial cancer Investing.com Nigeria

Published: Dec. 23, 2025, 2:36 a.m.
The Impact of Central Sensitization on Patients Perceived Improvement and Quality of Life Following Surgery for Chronic Pelvic Pain: A Pilot Study.

To assess whether higher baseline Central Sensitization Inventory (CSI) scores are linked to quality-of-life outcomes and patient's impression of improvement after surgery for chronic pelvic pain.

Published: Dec. 23, 2025, midnight
Endometriosis: From Genes to Global Burden.

Endometriosis has a significant impact on the social, psychological, psychosomatic, and physical aspects of women's lives. There is increasing evidence that endometriosis has to be seen as a systemic and …

Published: Dec. 23, 2025, midnight
Rare surgery brings relief to endometriosis patient at Ottawa hospital - CBC

Rare surgery brings relief to endometriosis patient at Ottawa hospital CBC

Published: Dec. 22, 2025, 9 a.m.
First patient dosed in phase 3 trial evaluating ENHERTU in endometrial cancer By Investing.com - Investing.com South Africa

First patient dosed in phase 3 trial evaluating ENHERTU in endometrial cancer By Investing.com Investing.com South Africa

Published: Dec. 22, 2025, 8:15 a.m.
DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer - The AI Journal

DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer The AI Journal

Published: Dec. 22, 2025, 7:31 a.m.
DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer - itemonline.com

DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer itemonline.com

Published: Dec. 22, 2025, 7:30 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!